FOUNDAYO 5.5 MG TABLET
FDA nonproprietary name: orforglipron
For 30 tablets
Pharmacies pay
$624.57 filed
30 × $20.81886 per EA
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare
We don’t know yet
No Medicare reference price. Part D: OpenBill did not match this NDC to a usable Medicare Part D spending row. Either Part D has none for it, or the rows that share its name could not safely be tied to it (for example, they mix units, routes or release forms, or the drug is sold over the counter, which Part D does not cover). Part B: This NDC is not in the current quarter’s Medicare Part B NDC-HCPCS crosswalk, so it has no Part B payment limit.
The spread
We don’t know yet
There is no Medicare figure to compare with, so there is no spread.
Cost-plus estimate
$723.26 estimated
$624.57 + $93.69 (15%) + $5.00 fee per fill = $723.26
This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out
OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)
Open the interactive card Change the quantity, type what you were charged, and see every record in full.
What it is
FOUNDAYO 5.5 MG TABLET is how the CMS NADAC file names this product. The FDA NDC Directory lists it as orforglipron, under the trade name “FOUNDAYO”.
FDA gives its dosage form as tablet, film coated and its route as oral.
The labeler, the company named on the label, is Eli Lilly and Company.
FDA’s Established Pharmacologic Class for it is GLP-1 Receptor Agonist.
The NADAC file of 2026-10-14 prices it under 2 NDCs (National Drug Codes); the FDA directory lists 1 of them.
NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.
What pharmacies pay
Pharmacies pay $624.57 for 30 tablets (30 × $20.81886 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.
NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.
What NADAC measures · Why 30 tablets · NADAC explanation codes
All 2 NDCs
- 00002-4794-01 · not listed as a package in the FDA directory · $20.81886 per EA · eff. 2026-09-23 filed
- 00002-4794-31 · Eli Lilly and Company · $20.81886 per EA · eff. 2026-09-23 filed
Other strengths, forms and brands
3 other products in the NADAC file share the FDA nonproprietary name orforglipron with FOUNDAYO 5.5 MG TABLET.
| Product | Pharmacies pay per unit | Medicare per unit |
|---|---|---|
| FOUNDAYO 0.8 MG TABLET | $20.89256 per EA filed | We don’t know yet |
| FOUNDAYO 2.5 MG TABLET | $20.83709 per EA filed | We don’t know yet |
| FOUNDAYO 5.5 MG TABLET this page | $20.81886 per EA filed | We don’t know yet |
| FOUNDAYO 9 MG TABLET | $20.8537 per EA filed | We don’t know yet |
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Compared with its class
The middle of its 2 NDCs’ NADAC prices is $20.81886 per EA filed.
Of the 13 other products in FDA’s GLP-1 Receptor Agonist class priced per EA, 13 have a higher middle NADAC price and 0 a lower one. The one in the middle is RYBELSUS 14 MG TABLET, at $33.18852 per EA filed (eff. 2026-09-23).
Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
What Medicare paid
We don’t know yet; the card above says why.
Which Medicare figure OpenBill compares · How Part D is matched · How Part B is matched
What to ask at the counter
None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.
- What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
- These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.
Related pages
Its pharmacologic class
Related in the same class
- MOUNJARO 10 MG/0.5 ML PEN
- TRULICITY 0.75 MG/0.5 ML PEN
- RYBELSUS 14 MG TABLET
- SOLIQUA 100 UNIT-33 MCG/ML PEN
- LIRAGLUTIDE 2-PAK 18 MG/3 ML